rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Armando Anido

Director

Company insider

Files Form 4 as: Director, Scynexis; Chairman & Chief Exec. Officer, Zynerba Pharmaceuticals; Director, Vaxart; Chief Executive Officer, Nupathe; Director, Adolor; CEO & President, Auxilium Pharmaceuticals; EVP, Sales and Mktg, Medimmune Inc /de.

Every Form 4 they filed

In numbers

Trades disclosed
152
Buys
4
Sells
12
Bought
$219K
Sold
$4.1M
Companies
7
Companies where not an officer
3
First trade
3 Feb 2006
Last trade
26 Jun 2026
Last filed
30 Jun 2026

Companies traded

Where they are an officer
Zynerba PharmaceuticalsDirector, Officer · last 10 Oct 20233 buys · 3 sells
NupatheDirector, Officer · last 21 Feb 20140 buys · 0 sells
Auxilium PharmaceuticalsDirector, Officer · last 7 Oct 20110 buys · 8 sells
Medimmune Inc /deOfficer · last 3 Feb 20060 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
SCYX ScynexisDirector · Biotechnology · last 26 Jun 20261 buy · 0 sells
VaxartDirector · Biotechnology · last 18 May 20170 buys · 0 sells
AdolorDirector · last 7 Dec 20110 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Jun 2026filed 30 Jun 2026SCYX ScynexisBiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX ScynexisBiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2025filed 30 Jun 2025SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
26 Jun 2025filed 30 Jun 2025SCYX ScynexisBiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
20 Jun 2024filed 21 Jun 2024SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
20 Jun 2024filed 21 Jun 2024SCYX ScynexisBiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
10 Oct 2023filed 11 Oct 2023Zynerba Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—190,000filing
10 Oct 2023filed 11 Oct 2023Zynerba PharmaceuticalsSEC FORM 4 Code U—566,722filing
10 Oct 2023filed 11 Oct 2023Zynerba PharmaceuticalsSEC FORM 4 Code A—240,000filing
10 Oct 2023filed 11 Oct 2023Zynerba PharmaceuticalsSEC FORM 4 Code U—610,000filing
10 Oct 2023filed 11 Oct 2023Zynerba PharmaceuticalsSEC FORM 4 Code U—26,595filing
10 Oct 2023filed 11 Oct 2023Zynerba PharmaceuticalsSEC FORM 4 Code U—13,297filing
13 Sep 2023filed 14 Sep 2023Zynerba PharmaceuticalsSEC FORM 4 Sold$24K17,830 at $1.33filing
12 Sep 2023filed 14 Sep 2023Zynerba PharmaceuticalsSEC FORM 4 Code A—64,747filing
15 Jun 2023filed 23 Jun 2023SCYX ScynexisBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
15 Jun 2023filed 20 Jun 2023SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
8 Feb 2023filed 9 Feb 2023Zynerba PharmaceuticalsSEC FORM 4 Code F$7,52812,547 at $0.60filing
7 Feb 2023filed 9 Feb 2023Zynerba PharmaceuticalsSEC FORM 4 Code A—45,406filing

News

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYX · manilatimes.net · 6 Oct 2026

0 headlines in the last 90 days name Armando Anido; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care1
Not placed15

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.